Saturday 17 October 2026
Export ZYBT’s income statement to Excel — free account
Zhengye Biotechnology Holding Limited
ZYBT Healthcare Drug Manufacturers Specialty & Generic
Zhengye Biotechnology Holding Limited’s revenue for fiscal 2025 (year ended December 2025) was $16.6 million, down 34.8% from fiscal 2024.
1.43
0.07
−4.67%
Follow ZYBT
| Dec '25 | Jun '25 | Dec '24 | Jun '24 | Older periods | |
|---|---|---|---|---|---|
| 0.00% | — | — | — |
+1 more TTM period Free account |
|
| 0.00% | — | — | — | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | — | — | |
Free Cash Flow |
5.34 | 9.33 | — | — | |
Capital Expenditures |
(2.27) | (3.00) | — | — | |
| Other line items | |||||
Cash ROIC |
8.62% | 13.41% | 0.00% | 0.00% | |
Accounts Receivable Turnover |
0.00 | — | — | — | |
Accounts Payable Turnover |
0.00 | — | — | — | |
Inventory Turnover |
0.00 | — | — | — | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | — | — | |
Depreciation/Fixed assets |
0.20 | 0.29 | 0.00 | 0.00 | |
Capex/Depreciation |
(0.22) | (0.30) | — | — | |
Operating CF per Share |
0.00 | 0.00 | — | — | |
Capex per Share |
0.00 | 0.00 | — | — | |
Capex to Sales |
0.00 | 0.00 | — | — |
Columns are period end dates